Page last updated: 2024-12-07
methyldeoxyspergualin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
15-deoxymethylspergualin: act on the proliferation & differentiation of T cells which respond to growth factors, such as IL-2 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 126996 |
CHEMBL ID | 1771562 |
SCHEMBL ID | 9772181 |
MeSH ID | M0206705 |
Synonyms (19)
Synonym |
---|
15-deoxy-11-o-methylspergualin |
114760-35-9 |
heptanamide, 7-((aminoiminomethyl)amino)-n-(2-((4-((3-amino propyl)amino)butyl)amino)-1-methoxy-2-oxoethyl)-, (s)- |
(-)-15-deoxy-11-o-methylspergualin |
medsg |
deoxymethylspergualin |
methyldeoxyspergualin |
15-medsg |
15-deoxymethylspergualin |
heptanamide, 7-((aminoiminomethyl)amino)-n-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-methoxy-2-oxoethyl)- |
deoxymethyspergualin |
1-amino-19-guanidino-11-methoxy-4,9,12-triazanonadecane-10,13-dione |
98629-44-8 |
CHEMBL1771562 |
n-[4-(3-aminopropyl)aminobutyl]-2-(7-guanidinoheptanamido)-2-methoxyethanamide |
HFNDGMJKLKYYRZ-UHFFFAOYSA-N |
SCHEMBL9772181 |
DTXSID90913155 |
n-[2-({4-[(3-aminopropyl)amino]butyl}imino)-2-hydroxy-1-methoxyethyl]-7-carbamimidamidoheptanimidic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID595073 | Chemical stability of the compound in aqueous buffer assessed as half life at pH 7 by thin layer chromatography | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. |
AID595046 | Chemical stability of the compound in aqueous buffer assessed as half life at pH 8 by thin layer chromatography | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. |
AID595048 | Antibacterial activity against Escherichia coli | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. |
AID595049 | Antibacterial activity against Bacillus subtilis | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. |
AID595047 | Chemical stability of the compound in aqueous buffer assessed as half life at pH 10 by thin layer chromatography | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. |
AID595072 | Chemical stability of the compound in aqueous buffer assessed as half life at pH 5 by thin layer chromatography | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. |
AID595050 | Antibacterial activity against Staphylococcus aureus | 2011 | Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9 | Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (29)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (17.24) | 18.7374 |
1990's | 19 (65.52) | 18.2507 |
2000's | 3 (10.34) | 29.6817 |
2010's | 2 (6.90) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.41) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 29 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |